Variceal bleeding mortality in cirrhotic continues being 15%. Standard therapy and risk stratification decreased failure in bleeding control, rebleeding, and mortality. Objective: Describe clinical characteristics of cirrhotic with variceal bleeding between 2016 to 2020, the treatment performed, the failure to bleeding control, rebleeding, and mortality. Methods: Cross-sectional study of cirrhotic with variceal hemorrhage. Demographic and clinical data collected; performance of descriptive statistics, with mean, absolute and relative frequencies. Results: 158 patients included, mean age 59 years, 50% men, CHILD PUGH A 24%, B 45% and C 29%, MELD mean 15 points; etiology of cirrhosis autoimmune 33%, alcoholic 23%, NASH 13%. Previous bleeding 39%. In secondary prophylaxis 82%, 33% achieved beta-blockade hemodynamic goal. Use of vasoactive in 84%, terlipressin used in 97%. Restrictive transfusion therapy 39%. Use of prokinetic 16%. Antibiotic prophylaxis 83%, with ampicillin sulbactam 81%. Digestive endoscopy performed on average 7 hours after admission. Bleeding from esophagogastric varices 84%, GOVI 6%, and active bleeding 39%. Successful endoscopic band ligation in 79%, cyanoacrylate in 79% of gastric varices. 36% with indication for preemptive-TIPS, it was not performed in 46% with the clinical indication. 8% required esophageal stent placement. Rescue TIPS in 2%. Rebleeding rate at 5 days was 8%. Mortality of 7% at 6 weeks Conclusion: The treatment of patients with variceal bleeding in our single-center experience was according to standard therapy described. Refractory bleeding and bleeding control failure were correlated with other studies published. Mortality was 7%. Secondary prophylaxis and preemptive-TIPS should be reinforced when the indication exist
